M20 Genomics and Xellar Biosystems Form Strategic Partnership to Advance Virtual Biology Through Integrated Transcriptomics, Organ-on-Chip, and AI Technologies

Singapore, September 2026 – M20 Genomics, an innovator in high-throughput single-cell and spatial transcriptomics technologies, and Xellar Biosystems, a pioneer in organ-on-chip (OoC) and AI-driven biological modeling technologies, have officially entered into a strategic partnership agreement.

Through this collaboration, the two companies will integrate their complementary technology capabilities: M20 Genomics’ high-throughput single-cell transcriptomics, spatial transcriptomics, and AI Virtual Cell (AIVC) modeling technologies with Xellar Biosystems’ OoC platforms, automated high-content imaging, and AI-based analysis capabilities.

Together, the companies aim to develop an integrated biological data foundation connecting molecular, cellular, tissue, and organ-level information, enabling the advancement of virtual organ and virtual tumor models for applications including target discovery, drug development, precision medicine research, and personalized cancer vaccine design.

Bridging Biological Complexity Through the Integration of Biology and Information Technology

The life science industry is increasingly shaped by the convergence of biotechnology (BT) and information technology (IT). However, conventional research models, including traditional two-dimensional cell culture and animal models, often fail to fully reproduce the complexity of human physiological and pathological environments, creating challenges for accurate target validation and efficient drug development.

To address these challenges, M20 Genomics and Xellar Biosystems are combining three emerging technology areas: high-throughput transcriptomic analysis, OoC technology, and artificial intelligence.

By integrating high-resolution molecular profiles with physiologically relevant biological models, the collaboration seeks to establish a cross-scale framework spanning molecular information, AIVC models, spatial tissue organization, biomimetic organs, and AI algorithms. This framework will align physiological and pathological data generated from OoC systems with high-resolution single-cell and spatial transcriptomic profiles to develop an integrated biological data foundation.

This integrated approach aims to enhance the understanding of complex biological systems and accelerate the translation of biological discoveries into therapeutic development.

Complementary Technologies Driving the Next Generation of Biological Modeling

M20 Genomics: Decoding Cellular and Spatial Biology at High Resolution

M20 Genomics develops next-generation single-cell and spatial transcriptomics technologies designed to capture high-dimensional biological information at high throughput and resolution.

Through its VITA high-throughput single-cell transcriptome platform and NATA spatial transcriptomics platform, M20 Genomics enables comprehensive analysis of cellular states and spatial molecular landscapes across diverse biological samples. A distinctive strength lies in microbial single-cell transcriptomics, which resolves gene expression and functional heterogeneity within and across microbial species. This capability generates scarce, high-resolution data on microbial cellular states, providing a valuable resource for investigating host–microbe interactions and expanding the biological diversity represented in AI training datasets.

These high-quality biological datasets provide an important foundation for AI-driven biological modeling. Building on its transcriptomic data capabilities, M20 Genomics is developing AIVC models to explore cellular state changes and biological responses under different conditions.

Within this collaboration, AIVC will serve as a computational bridge connecting molecular and cellular information with higher-order tissue and organ-level models, supporting the development of virtual biological systems.

Xellar Biosystems: Building Physiologically Relevant 3D Biological Models with Organ-on-Chip and AI Technologies

Xellar Biosystems focuses on OoC technologies, combining automated experimentation, 3D biological models, high-content imaging, and AI-based analysis to generate biologically relevant, high-dimensional datasets. Through OoC platforms, Xellar Biosystems recreates key aspects of human physiological and pathological environments by controlling factors including multicellular composition, vascularization, perfusion, and mechanical conditions.

Compared with traditional in vitro models, these systems provide platforms with improved physiological relevance for studying disease mechanisms, evaluating drug responses, and investigating biological processes.

By integrating automated experimental systems with high-content imaging and AI-based analysis, Xellar Biosystems enables the generation and interpretation of large-scale biological datasets, creating a foundation for more efficient biological research and drug development.

Advancing Virtual Organ and Virtual Tumor Models Through Cross-Scale Integration

Traditionally, physiological data generated from OoC systems and molecular information obtained through transcriptomic technologies have been analyzed separately, limiting the ability to connect molecular changes with tissue- and organ-level biological outcomes.

Through this strategic partnership, M20 Genomics and Xellar Biosystems aim to bridge these different biological scales by combining:

• High-resolution single-cell and spatial transcriptomic data,
• AIVC modeling approaches,
• OoC-derived physiological and phenotypic data,
• AI-based computational methods.

Based on this integrated biological framework, the companies will explore the development of virtual organ and virtual tumor models.

Potential applications include:

Advancing Target Discovery

By integrating cellular state information from AIVC models with virtual tumor and organ models, researchers may gain deeper insights into molecular changes and their relationship with complex tissue environments, supporting the identification and evaluation of potential therapeutic targets.

Improving Predictive Capabilities in Drug Development

The combination of computational modeling and OoC validation may provide new approaches for drug screening and evaluation, helping researchers assess therapeutic responses and biological effects in more physiologically relevant systems.

Enabling Precision Oncology Research and Personalized Vaccine Development

By combining patient-derived biological models, spatial transcriptomic information, and virtual tumor modeling approaches, this collaboration aims to support research into personalized cancer therapies and individualized vaccine design, including the study of tumor microenvironments and immune responses.

Building a New Framework for Understanding Complex Biological Systems

The strategic partnership between M20 Genomics and Xellar Biosystems represents an important step toward integrating molecular-level biological information with physiologically relevant organ-level models.

By combining high-throughput transcriptomics, spatial biology, OoC technologies, and AI-driven analysis, the two companies aim to establish new approaches for studying complex biological systems and advancing biomedical innovation.

M20 Genomics stated:
“M20 Genomics has been dedicated to developing high-throughput single-cell and spatial transcriptomics technologies and building high-quality biological datasets to advance AI-driven understanding of complex life systems. Xellar Biosystems brings strong expertise in OoC and 3D biological modeling technologies. Through this collaboration, we hope to integrate molecular and cellular data with physiologically relevant organ models, creating new opportunities for cross-scale biological modeling and predictive research.”

Xellar Biosystems stated:
“OoC technologies provide powerful platforms for modeling human physiological and pathological processes, while AI and biological data analysis provide new opportunities to interpret and predict complex biological behaviors. By combining Xellar Biosystems’ OoC capabilities with M20 Genomics’ expertise in single-cell transcriptomics, spatial transcriptomics, and AIVC-related data and algorithms, this collaboration will accelerate the development of virtual biological models and provide new tools for biomedical research.”